TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Intracranial haemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline in NIHSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient preparedness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: changes in the degree of headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: the improvement of quality of life(QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline in Periodontal Pocket Depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Clinical Attachment Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Modified Gingival Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a Static Physician's Global Assessment (sPGA) of (0,1) With at Least a 2-point Improvement From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90) From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Visual Analog Scale (VAS) score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change from baseline Western Ontario and McMaster University Osteoarthritis Index (WOMAC) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline SF-36 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: HVLT-R (Hopkins Verbal Learning Test-Revised)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: BVMT-R (Brief Visuospatial Memory Test-Revised)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: MDD Core Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of VSCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depth of tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemangioma height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Static and Dynamic Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin color and lightness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Infant stool consistency and frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of Patients Remaining in Study at 1 Year
Endpoint domain: Mortality/survival
Primary endpoint: Percent Changes of Serum Uric Acid Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Curve (AUC) from the time of dosing to the time of the last observed concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum high sensitivity C-reactive protein (HsCRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of postoperative severe complications
Endpoint domain: Adverse events/effects
Primary endpoint: Bladder Storage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bladder Emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bladder Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of hospital admissions for angioedema attack
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Proportion of drug users undertaking clinical and laboratory screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of decline of FVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: donor ovarian response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Inflammatory serum markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Oedematous changes in the brain and spinal cord
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Household Food Security
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Food Security Among Adults
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Food Security Among Children
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decrease in opioid prescription strength
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number and Frequency of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Total Cost of Emergency Room Visits and Hospital Days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mechanical Sensitivity Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Constant Heat Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Constant Heat Pain Unpleasantness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with Melanoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Buprenorphine plasma concentration levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All-Cause Mortality or Complications of MI
Endpoint domain: Mortality/survival
Primary endpoint: Protein concentrations in dried blood spots
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Classification accuracy of protein concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of MRM headache free PMPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change scores of Fugl-Meyer assessment (FMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of SAEs and treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: area under the concentration time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: area under the curve of small bowel water volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: lag-Time of sulfapyridine (orocecal transit times)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Doppler Resistance index (RI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Evaluation of Functional Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: exact localisation of impacted teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Proportion of VIA-, Xpert HPV-, and OncoE6-positive results that are correctly identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of VIA-, Xpert HPV-, and OncoE6-negative results that are correctly identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved markers of mortality
Endpoint domain: Mortality/survival
Primary endpoint: airway patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC(0-tlast))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child's responsiveness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in sputum neutrophil count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Small airway dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Symptoms evaluated by mMRC
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of moderate and severe exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: local control rate without severe complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Response to Dysphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with ocular and nonocular adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in Best Correct Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Central subfield thickness (CSFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Intraocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intent to Accept Screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Aberrant Behavior Checklist (ABC-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression Severity Score (CGI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Autism Treatment Evaluation Checklist (ATEC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Posterolateral Fusion Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Degree of watering
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HEMORR2HAGES
Endpoint domain: Adverse events/effects
Primary endpoint: HAS-Bled
Endpoint domain: Adverse events/effects
Primary endpoint: ATRIA
Endpoint domain: Adverse events/effects
Primary endpoint: shireman
Endpoint domain: Adverse events/effects
Primary endpoint: charlson
Endpoint domain: Adverse events/effects
Primary endpoint: standardised geriatric assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum plasma concentration of SKY0402
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Esophageal dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean Dose of Radiation Received by Fingernails
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chest tube drainage duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in language development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in socio-emotional development
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cancer cell involvement in lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Kidney Injury Biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Functional activity of HDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in the QT/QTc Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in clinical laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical failure rate at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With BAX 888-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Predictive markers of progression to malignant disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Horizontal Gingival Displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient respiratory comfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Change in Hemoglobin A1c (HbA1c) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of renal events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of P-selectin and GPIIbIIIa positive platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of platelet-monocyte aggregates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of platelet-neutrophil aggregates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cardiac failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of stringent complete response (sCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of minimal residual disease (MRD)-negative disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average daily use (hours)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Subjects Achieving Hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Sialometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intervention delay (days)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Success at 180 Days
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With At Least One Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Corneal cellular elements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall percent (%) agreement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dose-Normalized Area Under the Concentration-time Curve (AUC0-12h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-normalized Maximum Plasma Drug Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in lines and wrinkles of the décolleté
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety during urodynamics
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Onset of possible adverse events due to the taping treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Onset of possible adverse events due to the adhesive elastic taping treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Onset of possible events hindering the healing of the pressure ulcer under investigation
Endpoint domain: Adverse events/effects
Primary endpoint: AUC0-t and AUC0-∞
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Excretion of Oxycondone, Noroxycodone, Hydroxymorphine, Normethoxymorphone in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1- and 5-year survival
Endpoint domain: Mortality/survival
Primary endpoint: SF-36 Physical Component
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Tumor control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Deterioration in dry eye status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until first/initial hemodynamic stabilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl Meyer Upper Extremity Motor Evaluations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of biopsies performed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: exhaled and systemic nitric oxide production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time for successful fiberoptic tracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: mean time to recovery of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline of 6 Points on the Hopkins Verbal Learning Test-Revised (HVLT-R)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: RVNA Concentrations ≥0.5 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PRNT50 Titer ≥1:10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Intraoperative Calculated Total Blood Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Baseline expression Gen NFE2L2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Antioxidant capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Renal Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of sports-related injuries and illnesses
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of continuous glucose monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Connors-3 Parent Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lean body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in left ventricular mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in SF-36 RAND physical health composite
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Before discount spending on eligible fresh, frozen and canned fruits and vegetables
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Tricuspid valve regurgitation peak velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulmonary regurgitation peak velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Retinal nerve fiber layer thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically driven target lesion revascularization (CD-TLR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Skin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin barrier reconstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of Maximum Skin Conductance Response (SCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Initiation of sexual intercourse
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Bowel preparation level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Absence of stress incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of SLE flares with decrease or discontinuation of HCQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertical sagittal axis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in Pocket probing depth (PPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dual Task Cost (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced One or More Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Durable Response Rate (DRR) Using Modified World Health Organization (WHO) Response Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction of iron deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under Plasma Concentration-time Curve From Zero to Infinity (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC From Time 0 to the Last Quantifiable Concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uterine Artery Doppler
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Count of Patients With at Least One Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Malodor as Measured by Organoleptic Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Absolute Oral Bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to perform fetoscopic spina bifida repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Whole-body distribution of [68Ga]Ga-DOTA-Siglec-9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes